Last reviewed · How we verify
Evobrutinib MR-T1
At a glance
| Generic name | Evobrutinib MR-T1 |
|---|---|
| Also known as | M2951 |
| Sponsor | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |